GLP-1 agonist drugs essentially mimic the hormone’s action. Quite a few have been developed, including semaglutide, ...

Diabetes and weight loss drug semaglutide has been trialled in people with Alzheimer's. We explain what it means for dementia ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight ...

And Big Pharma’s not done cashing in on the weight-loss boom. Drugmakers are readying a new wave of next-level GLP-1 ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients. “ Ozempic is about to be ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral ...

The manufacturers of Ozempic and Mounjaro are creating oral weight loss medications that could change treatment methods.